The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Official Title: A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Study ID: NCT05653427
Brief Summary: The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Beijing Cancer Hospital, Beijing, , China
The First Hospital of Jilin University, Chang Chun Shi, , China
The Third Xiangya Hospital, Central South University, Changsha, , China
West China Hospital, Chengdu, , China
Chongqing Cancer Hospital, Chong Qing, , China
The Second Affiliated Hospital of Dalian Medical University, Dalian, , China
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fu Zhou Shi, , China
Nanfang Hospital, Guang Zhou Shi, , China
Zhejiang University First Hospital, Hang Zhou Shi, , China
Zhejiang Cancer Hospital, Hangzhou, , China
The Second Affiliatde Hospital To Nanchang University, Nan Chang Shi, , China
Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, , China
Xi An International Medical Center Hospital, XI An, , China
Name: Janssen Research & Development, LLC Clinical trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR